These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15765018)

  • 1. [Behavioral and pharmacological characteristics of mice lacking the dopamine transporter].
    Biala G
    Postepy Hig Med Dosw (Online); 2004; 58():560-4. PubMed ID: 15765018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter.
    Gainetdinov RR; Mohn AR; Bohn LM; Caron MG
    Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11047-54. PubMed ID: 11572967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin/dopamine interactions in a hyperactive mouse: reduced serotonin receptor 1B activity reverses effects of dopamine transporter knockout.
    Hall FS; Sora I; Hen R; Uhl GR
    PLoS One; 2014; 9(12):e115009. PubMed ID: 25514162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dopamine transporter: a crucial component regulating dopamine transmission.
    Jaber M; Jones S; Giros B; Caron MG
    Mov Disord; 1997 Sep; 12(5):629-33. PubMed ID: 9380041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons.
    Canseco-Alba A; Schanz N; Sanabria B; Zhao J; Lin Z; Liu QR; Onaivi ES
    Behav Brain Res; 2019 Mar; 360():286-297. PubMed ID: 30508607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in Dopamine Transporter Knock-out Rats.
    Leo D; Sukhanov I; Zoratto F; Illiano P; Caffino L; Sanna F; Messa G; Emanuele M; Esposito A; Dorofeikova M; Budygin EA; Mus L; Efimova EV; Niello M; Espinoza S; Sotnikova TD; Hoener MC; Laviola G; Fumagalli F; Adriani W; Gainetdinov RR
    J Neurosci; 2018 Feb; 38(8):1959-1972. PubMed ID: 29348190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localization of the delta-opioid receptor and dopamine transporter in the nucleus accumbens shell: implications for opiate and psychostimulant cross-sensitization.
    Svingos AL; Clarke CL; Pickel VM
    Synapse; 1999 Oct; 34(1):1-10. PubMed ID: 10459166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity.
    Gainetdinov RR; Wetsel WC; Jones SR; Levin ED; Jaber M; Caron MG
    Science; 1999 Jan; 283(5400):397-401. PubMed ID: 9888856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dopamine transporter expression level differentially affects responses to cocaine and amphetamine.
    Cagniard B; Sotnikova TD; Gainetdinov RR; Zhuang X
    J Neurogenet; 2014; 28(1-2):112-21. PubMed ID: 24673634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDMA "ecstasy" alters hyperactive and perseverative behaviors in dopamine transporter knockout mice.
    Powell SB; Lehmann-Masten VD; Paulus MP; Gainetdinov RR; Caron MG; Geyer MA
    Psychopharmacology (Berl); 2004 May; 173(3-4):310-7. PubMed ID: 14747902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cocaine reward and locomotion stimulation in mice with reduced dopamine transporter expression.
    Tilley MR; Cagniard B; Zhuang X; Han DD; Tiao N; Gu HH
    BMC Neurosci; 2007 Jun; 8():42. PubMed ID: 17584943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice.
    Del'Guidice T; Lemasson M; Etiévant A; Manta S; Magno LA; Escoffier G; Roman FS; Beaulieu JM
    Psychopharmacology (Berl); 2014 Jan; 231(1):109-22. PubMed ID: 23912772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How stimulant drugs may calm hyperactivity.
    Marx J
    Science; 1999 Jan; 283(5400):306. PubMed ID: 9925481
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter.
    Spielewoy C; Biala G; Roubert C; Hamon M; Betancur C; Giros B
    Psychopharmacology (Berl); 2001 Dec; 159(1):2-9. PubMed ID: 11797063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dopamine control of neuroendocrine functions. New findings based on the study of transgenic animals].
    Jaber M
    Ann Endocrinol (Paris); 1997; 58(6):427-35. PubMed ID: 9686001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotransmitter transporters as molecular targets for addictive drugs.
    Amara SG; Sonders MS
    Drug Alcohol Depend; 1998; 51(1-2):87-96. PubMed ID: 9716932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-quantum-dot tracking reveals altered membrane dynamics of an attention-deficit/hyperactivity-disorder-derived dopamine transporter coding variant.
    Kovtun O; Sakrikar D; Tomlinson ID; Chang JC; Arzeta-Ferrer X; Blakely RD; Rosenthal SJ
    ACS Chem Neurosci; 2015 Apr; 6(4):526-34. PubMed ID: 25747272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperactivity and impaired response habituation in hyperdopaminergic mice.
    Zhuang X; Oosting RS; Jones SR; Gainetdinov RR; Miller GW; Caron MG; Hen R
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1982-7. PubMed ID: 11172062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reward-enhancing effect of methylphenidate is abolished in dopamine transporter knockout mice: A model of attention-deficit/hyperactivity disorder.
    Ide S; Ikekubo Y; Hua J; Takamatsu Y; Uhl GR; Sora I; Ikeda K
    Neuropsychopharmacol Rep; 2018 Sep; 38(3):149-153. PubMed ID: 30175528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine transporter as a target molecule for psychostimulants.
    Sora I; Li B; Fumushima S; Fukui A; Arime Y; Kasahara Y; Tomita H; Ikeda K
    Int Rev Neurobiol; 2009; 85():29-33. PubMed ID: 19607959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.